Q-omics provides the consensus-scored CCDC194 profile across patient tissues and cancer cell-line models. CCDC194 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, CCDC194 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CCDC194 RNA expression shows 13,496 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where CCDC194 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CCDC194 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CCDC194 survival associations across molecular data types. CCDC194 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CCDC194 RNA expression–survival associations across cancer types. High CCDC194 expression shows unfavorable associations in KIRP, KIRC, LGG and UVM, but favorable associations in SKCM and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for CCDC194 RNA expression.
This table summarizes CCDC194 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CCDC194. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CCDC194 shows higher tumor expression in KIRC, HNSC, BLCA, COAD, STAD and BRCA. The KIRC box plot shows higher CCDC194 RNA expression in tumor versus normal tissue (log2 FC = +0.235, t-test p < 0.001).
This table shows molecular features associated with CCDC194 in patient tissues and cancer cell lines. In patient samples, CCDC194 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CCDC194 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma.
